Trial Profile
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jun 2016
Price :
$35
*
At a glance
- Drugs Quilizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Therapeutic Use
- Acronyms SOLARIO
- Sponsors Genentech
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society.
- 20 May 2012 Status changed from active, no longer recruiting to completed based on results being reported at the 108th International Conference of the American Thoracic Society.